Nasdaq GlobeNewswire

Zageno is Proud to Support Biotech Week Boston as BioProcess International Conference & Exhibition Hall Food Court Sponsor

Del

Visit us at the main entrance at the 1000 aisle for giveaways and demonstrations of the most-comprehensive online marketplace dedicated to life science research

CAMBRIDGE, Mass. USA and BERLIN, Germany, Aug. 27, 2018 (GLOBE NEWSWIRE) -- To celebrate its rapid growth and success in becoming the largest and fastest-growing online marketplace for the research scientist, Zageno Inc., is delighted to support Biotech Week Boston as a BioProcess International Conference & Exhibition Hall Food Court Sponsor. The conference takes place September 5 – 7, 2018, at the Hynes Convention Center Boston.

“Since the company was founded in 2015, the Boston area has been our home,” said Zageno Chief Executive Officer David Pumberger, Ph.D. “So, we are thrilled to act as co-hosts of Biotech Week Boston and help welcome the thousands of people from around the world who are expected to attend. Many of our customers and vendor partners will be there and we look forward to catching up in person. For those who may not be familiar with how Zageno helps world-leading biotech companies, startups, and the vendors that supply them, large and small — we welcome the opportunity to talk.”

Zageno Chief Revenue Officer Florian Wegener, M.D., M.B.A., Ph.D., commented, “If you look at the total scope of what Zageno delivers, there is no other offering that compares to the breadth and functionality of our platform. We have built a complete process bridge between the product comparison/selection and ordering aspect of the scientific workflow and the administrative procurement process.” 

Zageno overcomes challenges of comparing and selecting appropriate research products with an industry-specific tool — Zageno’s Scientific Score — which enables scientists to choose the best products to advance their science, using a ranking score based on millions of unbiased scientific publications, among other factors. The company also helps customers simplify and streamline their procurement process, typically saving substantial time and money, through better integration into their existing processes. 

And when additional assistance is needed, Zageno is staffed with experts that are accessible, knowledgeable, and helpful. A contingent of Zageno’s US-based team members will be available at a Zageno table located near the food court at the main entrance at the 1000 aisle

About Zageno Inc. (www.zageno.com;  twitter: @ZAGENOteam)
Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions’ procurement offices with leading life-science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising about five million products. What do we do? 1) We make purchasing transactions more efficient for both buyers and sellers. 2) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 3) We provide a valuable, expanded sales channel for our vendor partners. The growing Zageno team of 60 in Cambridge, USA, and Berlin, Germany, includes accessible experts in science, e-commerce, systems integration, and customer support. Our people work directly with customers to enable smarter, faster processes — allowing more time and resources for value-added science and better research results.

Attachment

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CP Kelco Announces Plans to Invest in Specialty Biogums Capabilities and Capacity Expansion19.11.2018 14:15Pressemelding

ATLANTA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In response to the strong global demand for specialty Biogums products, CP Kelco announced today its plans to invest in building capabilities and expanding production capacity. As a leading global producer and innovator of hydrocolloid solutions, CP Kelco is reinforcing its commitment to three Biogums product lines – gellan gum, specialty xanthan gum and diutan gum – through these key operational initiatives: Adding gellan gum production capabilities in the company’s Wulian, China facility to support growth in the Asia Pacific region; Expanding the overall capacity of the Wulian, China facility to support growth across all three specialty Biogums product lines; and Expanding the recently added gellan gum production capacity in the company’s Okmulgee, Oklahoma, USA facility. In addition to the planned investments in new production capabilities and capacity, CP Kelco is equally committed to ensuring its Biogums products meet the high standards o

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan19.11.2018 14:00Pressemelding

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan. Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML). This submission complements Invivoscribe’s prior

Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers19.11.2018 14:00Pressemelding

Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals Tested formulation is used in ongoing Phase 3 trial Data to be reviewed at Minerva’s roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the results from a prospective, double-blind, placebo-controlled, randomized single-escalating dose study in healthy subjects to evaluate the investigational drug roluperidone as monotherapy administered at nine ascending doses (16, 32, 64, 96, 128, 160, 19

Clutch Ranks SoftServe Among the Top Data Analytics Companies in Ukraine19.11.2018 13:00Pressemelding

AUSTIN, Texas, Nov. 19, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has been named a top data analytics consulting company in Ukraine for its high-quality service in technology transformation consulting by Clutch, a leading B2B research, ratings, and reviews company based in Washington D.C. SoftServe ranked ninth out of more than 140 firms in the data analytics category. Clutch determines its industry leader rankings by using a methodology that evaluates companies based on industry expertise and the ability to deliver. Additional criteria includes services offered, types of clients, case studies, brand reputation, and visibility within the target market. “As part of Clutch’s service, we provide business to business firms the opportunity to evaluate companies and their competitors so that they can find the best partner to meet their needs,” said Jackie Faselt, Business Analyst at Clutch. “SoftServe’s technical expertise and positi

GridGain Experts Showcase the Power of In-Memory Computing at Multiple Industry Events19.11.2018 09:00Pressemelding

FOSTER CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Experts from GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, is organizing or taking part in multiple webinars, conferences and meetups during November and December to share the latest information and developments related to in-memory computing technology and business trends. “The performance challenges facing companies as they undertake digital transformation are vast, and for many companies an in-memory computing platform is the only cost-effective, easy-to-deploy technology capable of delivering the speed and scalability necessary to overcome many of those challenges,” said Terry Erisman, vice president of marketing at GridGain Systems. “Our experts travel the world to share practical advice on how to leverage the power of in-memory computing.” Conferences AWS Re:Invent 2018 – November 26, 2018 – GridGain CTO and Co-Founder Nikita Ivanov will speak on the topic of “In-Memor

Benchmark Assays 5.90 Metres at 12.62g/t AuEq From 2015 Drill-Hole That Also Provided 385.5 AuEq From Historical Assay19.11.2018 09:00Pressemelding

EDMONTON, Alberta, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Benchmark Metals Inc. (the “Company” or “Benchmark”) (TSX-V: BNCH) (OTCQB: CYRTF) (WKN: A2JM2X) - is pleased to announce drill-hole assays from the infill and shoulder sampling program of historical drill-core at the Lawyers Gold & Silver Project, located in the Golden Triangle region of British Columbia, Canada. Selected results from new and combined historical intersections include 5.9m at 12.62g/t AuEq (hole CC15-15), 63.75m at 1.59g/t AuEq (hole DR15-05), and 1.68m at 10.94g/t AuEq (hole DR15-01)*. CEO John Williamson commented, “Drill-hole assay results from selected historical holes continue to indicate that much of the Gold-Silver Lawyers project contains significant mineralization at surface and at shallow depths. Results from the Cliff Creek Zone and Dukes Ridge Zone are providing high-grade intersections that are enveloped by larger bulk tonnage style intersections. We anticipate more results from 2018 infill and step-out d

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom